Summit Therapeutics Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
SMMT$17.84+9.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FINANCIAL INFORMATION Financial Statements (Unaudited)Condensed Consolidated Balance Sheets
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
Condensed Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $106,515 | $225,266 |
| Restricted cash | 316 | 316 |
| Short-term investments | 492,216 | 488,182 |
| Prepaid expenses and other current assets | 17,551 | 6,537 |
| Total current assets | 616,598 | 720,301 |
| Non-current assets: | ||
| Property and equipment, net | 1,664 | 1,059 |
| Operating lease right-of-use assets | 19,398 | 20,616 |
| Goodwill | 1,965 | 2,001 |
| Other assets | 8,231 | 7,205 |
| Total assets | $647,856 | $751,182 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $27,549 | $20,292 |
| Accrued liabilities | 44,317 | 32,100 |
| Accrued compensation | 7,073 | 14,925 |
| Operating lease liabilities, current portion | 3,179 | 3,388 |
| Other current liabilities | 1,148 | 2,283 |
| Total current liabilities | 83,266 | 72,988 |
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 16,859 | 17,502 |
| Other non-current liabilities | 1,799 | 1,832 |
| Total liabilities | 101,924 | 92,322 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 7,760 | 7,754 |
| Additional paid-in capital | 3,024,387 | 2,947,805 |
| Accumulated other comprehensive loss | (2,632) | (2,540) |
| Accumulated deficit | (2,483,583) | (2,294,159) |
| Total stockholders' equity | 545,932 | 658,860 |
| Total liabilities and stockholders' equity | $647,856 | $751,182 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.